New combo aims to remove stubborn throat cancer with chemo-immunotherapy and surgery
NCT ID NCT07129772
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 32 times
Summary
This study tests whether giving pembrolizumab (an immunotherapy) plus chemotherapy before and after surgery can help people with nasopharyngeal cancer that has come back in the same area. About 53 adults will receive the drug combination, then have minimally invasive surgery to remove any remaining tumor, followed by more pembrolizumab. The goal is to see if this approach can clear all cancer cells and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Clinical Oncology, Queen Mary Hospital
Hong Kong, Hong Kong
Conditions
Explore the condition pages connected to this study.